The FDA holds its first CBD hearing in May, as the agency plans to legalize the compound in food and beverages.
The Food and Drug Administration will hold its first public hearing on the legalization of CBD in food and beverages, to determine how to regulate the newly legalized cannabis product. The hearing will take place on May 31.
The agency wants data on the safety of CBD in food products and comments on how it could regulate manufacturing, marketing and labeling, according to a notice released Tuesday in the Federal Register.
Scott Gottlieb, outgoing FDA Commissioner, appointed Amy Abernethy, Senior Assistant Commissioner, and Lowell Schiller, Senior Associate Commissioner for Policy. They will co-chair a high-level working group to evaluate this issue.
"It is essential that we answer these unanswered questions about the topic of CBD and other cannabis-derived products to help inform FDA's regulatory oversight of these products: especially as the agency examines 'It would be appropriate to allow the use of CBD in dietary supplements and other foods,' said Gottlieb in a statement on Tuesday.
CBD, the abbreviation for cannabidiol, is a non-psychoactive compound found in the cannabis plant that promises to relax the body without altering the mind like THC. Congress has legalized the CBD derived from hemp last December.
This situation was expected to lead to an increase in the number of consumer products infused with the cannabis compound. However, FDA rules prohibiting the addition of CBD in food and beverages have kept most large companies out of business, although a number of start-ups have still made the leap.
Faced with congressional calls, the FDA sought a solution privately. She will now make her efforts public, first with the meeting to be held at her headquarters near Washington, DC Gottlieb said the working group plans to share its findings as early as this summer.
"This is a complicated subject and we expect it to take some time to solve it completely," he said. "Nevertheless, we are deeply focused on this issue and we are committed to continuing to engage relevant stakeholders as we consider potential avenues for the future.
The FDA and the Federal Trade Commission on Tuesday sent warning letters to three companies: Advanced Spine and Pain Relievus, Nutra Pure and PotNetwork Holdings; for allegedly making unproven claims about their CBD products, such as helping to treat cancer and Alzheimer's disease.
"The FDA continues to be concerned about the proliferation of blatant medical claims about products that claim to contain CBD that have not been approved by the FDA, such as products and companies that today receive letters of approval. warning, "said Mr Gottlieb.
Many other CBD-related companies make exaggerated health claims and this is the main reason why the FDA makes the speech public.